Loading clinical trials...
Loading clinical trials...
A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus.
Conditions
Interventions
BI 456906
Placebo
+1 more
Locations
80
United States
National Research Institute
Huntington Park, California, United States
National Research Institute
Los Angeles, California, United States
Valley Clinical Trials, Inc.
Northridge, California, United States
Indago Research and Health Center
Hialeah, Florida, United States
Meridien Research
Lakeland, Florida, United States
San Marcus Research Clinic, Inc.
Miami, Florida, United States
Start Date
April 30, 2020
Primary Completion Date
October 8, 2021
Completion Date
November 4, 2021
Last Updated
November 29, 2022
NCT06513026
NCT06329375
NCT06945406
NCT06959901
NCT06574035
NCT06861062
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions